Amphastar Pharmaceuticals, Inc.
Long

Breakout Buy in AMPH

325
After a deep pullback in August and September, Amphastar is coming back in a big way. Following its early-November earnings report, the stock is up more than 20% in the last few weeks. It has reclaimed all its moving averages and is now consolidation with a pivot at $58.

Volume has dried up nicely during this consolidation which is typically a sign the stock is becoming harder to buy and getting concentrated into strong institutional hands.

One might consider buying on a high-volume move above $58.

Aviso legal

As informações e publicações não se destinam a ser, e não constituem, conselhos ou recomendações financeiras, de investimento, comerciais ou de outro tipo fornecidos ou endossados pela TradingView. Leia mais nos Termos de Uso.